FAKTOR-OPTIONSSCHEIN - MODERNA | Market Closed - Boerse Frankfurt Warrants 15:41:53 2024-06-28 EDT | ||
| 0.91 EUR | -5.21% |
|
| Current month | -32.33% | ||
| 1 month | -41.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.9 | -6.25% |
| 24-06-27 | 0.96 | -2.04% |
| 24-06-26 | 0.98 | -19.67% |
| 24-06-25 | 1.22 | +0.83% |
| 24-06-24 | 1.21 | +2.54% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 03:41 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SF5DCA |
| ISIN | DE000SF5DCA1 |
| Date issued | 2021-10-06 |
| Strike | 325.7 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 24.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.89 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.01 € |
| Spread % | 1.09% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Certificates
- Certificat
